MetaVia Inc. (MTVA)

NASDAQ: MTVA · Real-Time Price · USD
0.6730
-0.0070 (-1.03%)
Jun 27, 2025, 9:23 AM - Market open
-1.03%
Market Cap 13.18M
Revenue (ttm) n/a
Net Income (ttm) -24.55M
Shares Out 19.59M
EPS (ttm) -2.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 876
Open n/a
Previous Close 0.6800
Day's Range n/a
52-Week Range 0.6326 - 5.3000
Beta 0.19
Analysts Strong Buy
Price Target 7.50 (+1,014.41%)
Earnings Date Aug 13, 2025

About MTVA

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 9
Stock Exchange NASDAQ
Ticker Symbol MTVA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for MTVA stock is "Strong Buy." The 12-month stock price forecast is $7.5, which is an increase of 1,014.41% from the latest price.

Price Target
$7.5
(1,014.41% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session

CAMBRIDGE, Mass. , June 21, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation ...

6 days ago - PRNewsWire

MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as ...

17 days ago - GlobeNewsWire

MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions

CAMBRIDGE, Mass. , June 4, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract h...

23 days ago - PRNewsWire

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

Announced Positive Top-Line Phase 1 MAD Trial Results for DA-1726 in Obesity, Demonstrating Compelling Weight Loss and Best-in-Class Potential for Glucose Control, Waist Reduction and Tolerability Add...

6 weeks ago - PRNewsWire

MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

CAMBRIDGE, Mass. , May 9, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) ("MetaVia"), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a priva...

7 weeks ago - PRNewsWire

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

DA-1241 Significantly Decreased Plasma ALT levels, with a Mean Reduction of 22.8 U/L After 16 Week-Treatment Controlled Attenuation Parameter (CAP) Score Improved by 23.0 dB/m, Indicating Reduced Live...

7 weeks ago - PRNewsWire

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

CAMBRIDGE, Mass. , April 23, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract...

2 months ago - PRNewsWire

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

A Dose-Dependent Response in Body Weight Reduction Was Observed Between 8 mg and 32 mg Doses Change in BMI and Body Weight Adjusted for Height In the Treatment Groups, Showed a Significant Difference ...

2 months ago - PRNewsWire

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

With No Titration, Demonstrated Compelling Maximum Weight Loss of 6.3% and  Mean Weight Loss of 4.3% at Day 26 at 32 mg Dose (p=0.0005) Demonstrated Strong Signal of GLP-1R Efficacy with Maximum Lower...

2 months ago - PRNewsWire

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

Top-Line Data From MAD Part  2  of the Phase 1 Trial of DA-1726 Expected in April of 2025 Announced Positive Top-Line 16-Week Results from the Phase 2a Trial of DA-1241 for the Treatment of MASH, in D...

3 months ago - PRNewsWire

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

CAMBRIDGE, Mass. , Jan. 10, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it is holdin...

6 months ago - PRNewsWire

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

New Nasdaq Ticker Symbol will be MTVA CAMBRIDGE, Mass. , Nov. 18, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming card...

7 months ago - PRNewsWire

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

CAMBRIDGE, Mass. , Nov. 13, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced ...

8 months ago - PRNewsWire

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Reported Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity, Revealing Favorable Safety, Tolerability and Dose-Linear Pharmacokine...

8 months ago - PRNewsWire

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Topline Data Readout From Part 1 and Part 2 Expected in December 2024 CAMBRIDGE, Mass. , Nov. 4, 2024 /PRNewswire/ --  NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology comp...

8 months ago - PRNewsWire

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

CAMBRIDGE, Mass. , Oct. 1, 2024 /PRNewswire/ --  NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced ...

9 months ago - PRNewsWire

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Data Revealed Favorable Safety, Tolerability and Dose-Linear Pharmacokinetics (PK) Top-Line Data Readout from the MAD Part 2 Expected in the First Quarter of 2025 Planned Phase 1 Part 3 Will Evaluate ...

9 months ago - PRNewsWire

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

CAMBRIDGE, Mass. , Sept. 3, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced ...

10 months ago - PRNewsWire

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Successfully Completed a Financing of up to $70 Million, With $20 Million Upfront and an Additional $50 Million of Aggregate Gross Proceeds Upon the Exercise in Full of Clinical Milestone-Based Warran...

11 months ago - PRNewsWire

NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

No Significant Issues Encountered During the Single Ascending Dose (SAD) Study, Allowing for Previously Reported Accelerated Start to Multiple Ascending Dose (MAD) Part 2 Top Line Data Readout from SA...

11 months ago - PRNewsWire

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

Collaboration to Leverage ImmunoForge's ELP Platform Technology Which Can Increase the Half-Life of a Drug by up to 200 Times CAMBRIDGE, Mass. , Aug. 6, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, I...

11 months ago - PRNewsWire

NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01

CAMBRIDGE, Mass. , July 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today a...

11 months ago - PRNewsWire

NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July

CAMBRIDGE, Mass. , July 11, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced ...

1 year ago - PRNewsWire

NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Top-Line Data Readout From the Single Ascending Dose Part 1 Expected in the Third Quarter of 2024, and From the Multiple Ascending Dose Part 2 in the First Quarter of 2025 Planned Part 3 Will Assess T...

1 year ago - PRNewsWire

NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

$20 million upfront with up to an additional $50 million of aggregate gross proceeds upon the exercise in full of clinical milestone-linked Series Warrants are expected to provide cash runway to compl...

1 year ago - PRNewsWire